Comparing Cynata Therapeutics (OTCMKTS:CYYNF) & Tectonic Therapeutic (NASDAQ:TECX)

Cynata Therapeutics (OTCMKTS:CYYNF) and Tectonic Therapeutic (NASDAQ:TECX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, valuation, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Cynata Therapeutics and Tectonic Therapeutic, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cynata Therapeutics	0	0	0	0	0.00
Tectonic Therapeutic	1	0	5	1	2.86

Tectonic Therapeutic has a consensus target price of $81.50, indicating a potential upside of 296.40%. Given Tectonic Therapeutic’s stronger consensus rating and higher probable upside, analysts clearly believe Tectonic Therapeutic is more favorable than Cynata Therapeutics.

Institutional & Insider Ownership

62.6% of Tectonic Therapeutic shares are held by institutional investors. 38.0% of Tectonic Therapeutic shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Risk & Volatility

Cynata Therapeutics has a beta of -0.36, meaning that its stock price is 136% less volatile than the S&P 500. Comparatively, Tectonic Therapeutic has a beta of 3.72, meaning that its stock price is 272% more volatile than the S&P 500.

Profitability

This table compares Cynata Therapeutics and Tectonic Therapeutic’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cynata Therapeutics	N/A	N/A	N/A
Tectonic Therapeutic	N/A	-27.11%	-25.88%

Valuation and Earnings

This table compares Cynata Therapeutics and Tectonic Therapeutic”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cynata Therapeutics	N/A	N/A	N/A	N/A	N/A
Tectonic Therapeutic	N/A	N/A	-$57.98 million	($3.86)	-5.33

Summary

Tectonic Therapeutic beats Cynata Therapeutics on 7 of the 9 factors compared between the two stocks.

About Cynata Therapeutics

Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase I clinical trial for the treatment of graft versus host disease. It also develops CYP-004, which is in Phase III clinical trial used for the treatment of osteoarthritis; and CYP-006TK, a novel polymercoated silicon wound dressing for diabetic wounds. In addition, the company develops products for the treatment of asthma, heart attack, coronary artery disease, brain cancer, sepsis, acute respiratory distress syndrome, critical limb ischemia, idiopathic pulmonary fibrosis, and renal transplantation. Cynata Therapeutics Limited has a strategic partnership with Fujifilm to provide clinical and commercial manufacturing services for, and supply of, Cynata's Cymerus therapeutic mesenchymal stem cell products. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was incorporated in 2003 and is based in Cremorne, Australia.

About Tectonic Therapeutic

Tectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.